(Q38786658)

English

Targeting metastasis

scientific article published on March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Targeting metastasis (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

author name string

Patricia S Steeg

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27009393%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

0 references

publication date

1 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Nature Reviews Cancer

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27009393%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27009393%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27009393%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

201-218

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27009393%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

https://scigraph.springernature.com/pub.10.1038/nrc.2016.25

0 references

A new branch on the tree: next-generation sequencing in the study of cancer evolution.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Clinical opportunities and challenges in targeting tumour dormancy

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Systemic spread is an early step in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Dysfunctional telomeres promote genomic instability and metastasis in the absence of telomerase activity in oncogene induced mammary cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromat

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Evidence for induction of a tumor metastasis-receptive microenvironment for ovarian cancer cells in bone marrow and other organs as an unwanted and underestimated side effect of chemotherapy/radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Cisplatin and nifedipine: synergistic cytotoxicity against murine solid tumors and their metastases.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Real-time imaging reveals the single steps of brain metastasis formation

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Integrin α3β1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Src kinases as therapeutic targets for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A phase 2 trial of dasatinib in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Gene signature-guided dasatinib therapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A pooled analysis of bone marrow micrometastasis in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Neoantigens in cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

GAS6 receptor status is associated with dormancy and bone metastatic tumor formation

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Does tumour dormancy offer a therapeutic target?

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Inhibition of skeletal metastasis by ectopic ERalpha expression in ERalpha-negative human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Lysyl oxidase mediates hypoxic control of metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

miR-200-containing extracellular vesicles promote breast cancer cell metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi).

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Exosome removal as a therapeutic adjuvant in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Brain metastases as preventive and therapeutic targets

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Translational value of mouse models in oncology drug development

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

The discovery and development of antiretroviral agents

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Why does cancer therapy lack effective anti-metastasis drugs?

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Metastasis: a therapeutic target for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Metastatic cells can escape the proapoptotic effects of TNF-α through increased autocrine IL-6/STAT3 signaling

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Promoting colonization in metastatic HCC cells by modulation of autophagy

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A multigenic program mediating breast cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Rho kinase inhibitors block melanoma cell migration and inhibit metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Expression of snail in pancreatic cancer promotes metastasis and chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

ID genes mediate tumor reinitiation during breast cancer lung metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Loss of Androgen-Regulated MicroRNA 1 Activates SRC and Promotes Prostate Cancer Bone Metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Endogenous human microRNAs that suppress breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Interactions between cancer stem cells and their niche govern metastatic colonization

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Metastasis suppressors alter the signal transduction of cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

TGF-β signaling in myeloid cells is required for tumor metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Distinct phosphotyrosine-dependent functions of the ShcA adaptor protein are required for transforming growth factor β (TGFβ)-induced breast cancer cell migration, invasion, and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Differential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of a metastatic niche by stimulating G-CSF production.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Co-migration of colon cancer cells and CAFs induced by TGFβ₁ enhances liver metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Genes that mediate breast cancer metastasis to the brain

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

The vascular basement membrane as "soil" in brain metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

IL-6 receptor is a possible target against growth of metastasized lung tumor cells in the brain

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Premetastatic soil and prevention of breast cancer brain metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Expression of antigen processing and presenting molecules in brain metastasis of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Adaptation of energy metabolism in breast cancer brain metastases

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Serpins promote cancer cell survival and vascular co-option in brain metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Cilengitide treatment for malignant glioma: current status and future direction

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Perspective: The right trials

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

21 January 2018

Anti-vascular endothelial growth factor therapy in breast cancer: game over?

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Liposomal Arg-Gly-Asp analogs effectively inhibit metastatic B16 melanoma colonization in murine lungs

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Recruitment of a myeloid cell subset (CD11b/Gr1mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis*

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way.

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.25

31 March 2020

The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accumulation of extracellular matrix in the liver induces high metastatic potential of hepatocellular carcinoma to the lung.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The distribution of secondary growths in cancer of the breast. 1889

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Critical factors in the biology of human cancer metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Drg-1 gene suppresses tumor metastasis in prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27009393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRC.2016.25

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27009393%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27009393%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27009393%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38786658&oldid=2141005573"